A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C.
Chen CY, Chuang WL, Qin A, Zhang WH, Zhu LY, Zhang GQ, Chen JJ, Lo CC, Zhou X, Mao X, Shang J, Kuo HT, Xie W, Chen CH, Lo GH, Jun DW, Dang S, Tsai CY, Wang TF, Lai HH, Tseng KC, Huang YW, Chen PJ.
Chen CY, et al. Among authors: qin a.
JGH Open. 2022 Oct 10;6(11):782-791. doi: 10.1002/jgh3.12825. eCollection 2022 Nov.
JGH Open. 2022.
PMID: 36406648
Free PMC article.